Table of contents

Extended reports

• Detailed analysis of the cell infiltrate and the expression of mediators of synovial inflammation and joint destruction in the synovium of patients with psoriatic arthritis: implications for treatment (25 May, 2006)

  A W R van Kuijk, P Reinders-Blankert, T J M Smeets, B A C Dijkmans, P P Tak
• Changes in synovial tissue Jak-STAT expression in rheumatoid arthritis in response to successful DMARD treatment (7 June, 2006)

  J G Walker, M J Ahern, M Coleman, H Weedon, V Papangelis, D Beroukas, P J Roberts-Thomson, M D Smith
• Signs of inflammation in both symptomatic and asymptomatic muscles from patients with polymyositis and dermatomyositis (10 July, 2006)

  C Dorph, P Englund, I Nennesmo, I E Lundberg
• Etanercept 50 mg once weekly is as effective as 25 mg twice weekly in patients with ankylosing spondylitis (12 September, 2006)

  D van der Heijde, J C Da Silva, M Dougados, P Geher, I van der Horst-Bruinsma, X Juanola, I Olivieri, F Raeman, L Settas, J Sieper, J Szechinski, D Walker, M-P Boussuge, J S Wajdula, L Paolozzi, S Fatenejad
• A long-term, open-label trial of the safety and efficacy of etanercept (Enbrel) in patients with rheumatoid arthritis not treated with other disease-modifying antirheumatic drugs (15 March, 2006)

  L Klareskog, M Gaubitz, V Rodriguez-Valverde, M Malaise, M Dougados, J Wajdula
• Hippocampal atrophy in systemic lupus erythematosus (26 January, 2006)

  S Appenzeller, A D Carnevalle, L M Li, L T L Costallat, F Cendes
• Power Doppler ultrasonography and synovitis: correlating ultrasound imaging with histopathological findings and evaluating the performance of ultrasound equipments (17 May, 2006)

  J M Koski, S Saarakkala, M Helle, U Hakulinen, J O Heikkinen, H Hermunen
• Reactive haemophagocytic syndrome in adult-onset Still’s disease: a report of six patients and a review of the literature (15 March, 2006)

  J-B Arlet, D Le Thi Huong, A Marinho, Z Amoura, B Wechsler, T Papo, J-C Piette
• Are American College of Rheumatology 50% response criteria superior to 20% criteria in distinguishing active aggressive treatment in rheumatoid arthritis clinical trials reported since 1997? A meta-analysis of discriminant capacities (27 February, 2006)

  C P Chung, J L Thompson, G G Koch, I Amara, V Strand, T Pincus
• Patterns of cardiovascular risk in rheumatoid arthritis (22 June, 2006)

  D H Solomon, N J Goodson, J N Katz, M E Weinblatt, J Avorn, S Setoguchi, C Canning, S Schneeweiss
• Reproducibility and inter-reader agreement of a scoring system for ultrasound evaluation of hip osteoarthritis (25 May, 2006)

  E Qvistgaard, S Torp-Pedersen, R Christensen, H Bliddal
• An international study on starting tumour necrosis factor-blocking agents in ankylosing spondylitis (7 February, 2006) Free

  T Pham, R Landewé, S van der Linden, M Dougados, J Sieper, J Braun, J Davis, M Rudwaleit, E Collantes, R Burgos-Vargas, J Edmonds, I Olivieri, I van der Horst-Bruinsma, H Mielants, M Stone, P Emery, D van der Heijde
• Benefits of a programme taking advantage of patient-instructors to teach and assess musculoskeletal skills in medical students (17 May, 2006)

  M Bideau, P-A Guerne, M-P Bianchi, P Huber
• Efficacy of tumour necrosis factor blockers in reducing uveitis flares in patients with spondylarthropathy: a retrospective study (10 August, 2006)

  S Guignard, L Gossec, C Salliot, A Ruyssen-Witrand, M Luc, M Duclos, M Dougados
• Anti-signal recognition particle autoantibodies: marker of a necrotising myopathy (5 May, 2006)

  G J D Hengstman, H J ter Laak, W T M Vree Egberts, I E Lundberg, H M Moutsopoulos, J Vencovsky, A Doria, M Mosca, W J van Venrooij, B G M van Engelen
• Increased urinary type II collagen helical and C telopeptide levels are independently associated with a rapidly destructive hip osteoarthritis (28 March, 2006)

  P Garnero, N Charni, F Juillet, T Conrozier, E Vignon